Regional Webinars & Breaking News Updates
What’s the Latest on COVID-19?
Suggested Readings
End of the National Public Health Emergency for COVID-19: What Does It Mean for the Public?
Bonavitacola, J. Am J Manag Care. March 2, 2023.
Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, et al. N Engl J Med. 2022;386(15):1397-1408.
Distinct neutralizing antibody escape of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.
Qu P, Evans JP, Faraone J, et al. bioRxiv. 2022:2022.2010.2019.512891.
Wang Q, Iketani S, Li Z, et al. bioRxiv. 2022:2022.2011.2023.517532.
Improved neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent BA.4/5 vaccine.
Zou J, Kurhade C, Patel S, et al. bioRxiv. 2022:2022.2011.2017.516898.
Linked Resources
Clinical Practice Guidelines
COVID data tracker.
CDC.
Fact Sheet for Healthcare Providers: Emergency Use Authorization for bebtelovimab.
US Food and Drug Administration (FDA).
Fact Sheet: COVID-19 Public Health Emergency Transition Roadmap
DHHS.
Fact sheet for healthcare providers: emergency use authorization for PaxlovidTM.
FDA.
Highlights of prescribing information: Veklury® (remdesivir).
FDA.
NIH.
Related activities
Webcast
1.00 CME/CE
What’s the Latest on COVID-19? - West Region
Current Prevention and Treatment Strategies
| Faculty: | Eric S. Daar, MD; Monica Gandhi, MD. MPH |
| Release: | 11/28/2022 |
| Expiration: | 02/28/2023 |
Webcast
1.00 CME/CE
What’s the Latest on COVID-19? - Midwest Region
Current Prevention and Treatment Strategies
| Faculty: | Daniel Kaul, MD; Raymund R. Razonable, MD, FIDSA, FAST |
| Release: | 11/28/2022 |
| Expiration: | 02/28/2023 |
Webcast
1.00 CME/CE
What’s the Latest on COVID-19? - South Region
Current Prevention and Treatment Strategies
| Faculty: | Roger J. Bedimo, MD; Leigh Lewis Speicher, MD, MPH |
| Release: | 11/29/2022 |
| Expiration: | 03/01/2023 |
Webcast
1.00 CME/CE
What’s the Latest on COVID-19? - Northeast Region
Current Prevention and Treatment Strategies
| Faculty: | Elizabeth P. Clayborne, MD, MA; Lewis W. Teperman, MD |
| Release: | 12/08/2022 |
| Expiration: | 03/08/2023 |
0.25 CME/CE
Novel COVID-19 Subvariants and the Changing Treatment Landscape
A COVID-19 "Breaking News" Update
| Faculty: | Eric S. Daar, MD |
| Release: | 12/23/2022 |
| Expiration: | 12/23/2023 |
0.25 CME/CE
Updates to Preventing and Treating COVID-19 in Immunocompromised Patients
Effect of XBB.1.5, BQ.1, and BQ.1.1 Subvariants
| Faculty: | Lewis W. Teperman, MD, FACS |
| Release: | 01/27/2023 |
| Expiration: | 01/27/2024 |
0.25 CME/CE
Answers to Common Clinical Challenges in COVID-19
A COVID-19 "Breaking News" Update
| Faculty: | Elizabeth P. Clayborne, MD, MA |
| Release: | 02/28/2023 |
| Expiration: | 02/28/2024 |
0.25 CME/CE
Anti-SARS-CoV-2 mAbs as Preexposure Prophylaxis
Proof of Concept and Future Directions
| Faculty: | Raymund R. Razonable, MD, FIDSA, FAST |
| Release: | 03/10/2023 |
| Expiration: | 03/10/2024 |
0.25 CME/CE
The End of the COVID-19 Public Health Emergency
What Does This Mean for Your Practice?
| Faculty: | Leigh Lewis Speicher, MD, MPH |
| Release: | 05/11/2023 |
| Expiration: | 05/11/2024 |
